Navigation Links
Cornerstone Pharmaceuticals, Inc. Announces the Addition of World-Renowned Experts to Scientific and Medical Advisory Boards

CRANBURY, N.J., Feb. 8, 2017 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc. today announced a number of additions to its Scientific and Medical Advisory Boards, continuing the company's recent momentum of growth in its management team and governing and advisory bodies. Members of Cornerstone's Scientific and Medical Advisory Boards are highly regarded researchers and physicians within the fields of oncology, hematology and lymphoma. They will help strengthen Cornerstone's drug development and commercialization capabilities at a pivotal time in the company's lifecycle, and provide guidance on the company's clinical trial strategy.

"Innovation in oncology drug development requires a multidisciplinary team comprised of experts in the scientific and medical fields.  We have assembled unparalleled boards of scientific and medical advisors who will work with Cornerstone to help revolutionize anticancer treatment among our prime treatment targets: pancreatic cancer, acute myeloid leukemia and lymphoma," said Howard Jonas, Chairman of the Board of Cornerstone.  "The combination of skills among the world-renowned cell biologists, oncology researchers and clinical oncologists on the advisory boards will further enhance Cornerstone's ability to develop and advance our cutting-edge R&D pipeline."

Chi Van Dang, M.D., Ph.D., the incoming Chair of the Scientific and Medical Advisory Boards said, "The addition of such highly regarded and experienced scientific and medical advisors, better positions Cornerstone as an incoming leader in the growing field of metabolic cancer therapy. I am excited to have the opportunity to work alongside such uniquely qualified colleagues."

Chair of the Scientific and Medical Advisory Boards

Chi Van Dang, M.D., Ph.D.: Director of the Abramson Cancer Center of the University of Pennsylvania until July 1, 2017, when he will become Scientific Director of the Ludwig Institute for Cancer Research. Dr. Dang is considered by many to be the world's leading authority on cancer metabolism. Dr. Dang is also serving on Cornerstone's Board of Directors.

Scientific Advisory Board

  • Dafna Bar-Sagi, Ph.D.: Senior Vice President, Vice Dean for Science, Chief Scientific Officer, Professor, Departments of Biochemistry and Molecular Pharmacology, and Medicine, NYU Langone Medical Center
  • Navdeep S. Chandel, Ph.D.: David W. Cugell Professor of Medicine and Cell Biology at Northwestern University Feinberg School of Medicine; Author of "Navigating Metabolism" (Cold Spring Harbor Press)
  • Alec Kimmelman, M.D., Ph.D.: Professor, Department of Radiation Oncology, Chair, Department of Radiation Oncology, NYU Langone Medical Center
  • Gregg Semenza, M.D., Ph.D.: Director, Vascular Program, Institute for Cell Engineering; Professor of Pediatrics, Radiation Oncology and Molecular Radiation Sciences, Biological Chemistry, Medicine, and Oncology at the Johns Hopkins University School of Medicine. 2016 Lasker Award recipient
  • Medical Advisory Board

    Pancreatic Cancer Advisors

  • Jordan D. Berlin, M.D.: Co-leader, Gastrointestinal Cancer Research Program, Professor of Medicine (Hematology/Oncology), Director, Phase I Program, Medical Oncologist, Vanderbilt-Ingram Cancer Center
  • J. Randolph Hecht, M.D.: Director, Gastrointestinal Cancer Program, Professor of Clinical Medicine, David Geffen School of Medicine at UCLA
  • William Isacoff, M.D.: Department of Medicine, David Geffen-UCLA School of Medicine; Board of Directors of the Jonsson Comprehensive Cancer Foundation
  • Philip A. Philip, M.D., Ph.D., F.R.C.P.: Professor of Oncology and Pharmacology, Leader, GI and Neuroendocrine Oncology, Vice President of Medical Affairs, Karmanos Cancer Center, Wayne State University
  • Heloisa P. Soares, M.D., Ph.D.: Medical Oncologist, Department of Gastrointestinal Oncology, Moffitt Cancer Center
  • Acute Myeloid Leukemia Advisors

  • Jorge Cortes, M.D.: Deputy Chair and Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center
  • Bayard L. Powell, M.D.: Section Chief, Hematology & Oncology, Associate Director for Clinical Research, Comprehensive Cancer Center, Professor, Hematology & Oncology, Wake Forest Baptist Medical Center
  • Mikkael Sekeres, M.D.: Director, Leukemia Program, Vice-chair for Clinical Research, Cleveland Clinic's Taussig Cancer Institute
  • Richard M. Stone, M.D.: Professor of Medicine, Harvard Medical School; Associate Physician, Medicine, Brigham And Women's Hospital; Director, Adult Leukemia Program, Dana-Farber Cancer Institute
  • Lymphoma Advisors

  • Craig H. Moskowitz, M.D.: Hematologist, Clinical Director of the Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center
  • Steven I. Park, M.D.: Director, Lymphoma Program, Associate Professor of Medicine, UNC Lineberger Comprehensive Cancer Center
  • About Cornerstone Pharmaceuticals, Inc.

    Cornerstone Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Cornerstone's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone's first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit:

    Safe Harbor Statement

    This press release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

    Contact: Jacob JonasPublic Relations, Cornerstone Pharmaceuticals, Inc. Kara GolubJFK Communications,

    To view the original version on PR Newswire, visit:

    SOURCE Cornerstone Pharmaceuticals, Inc.
    Copyright©2017 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cornerstone Pharmaceuticals, Inc. Announces Additions to its Board of Directors: Jean-Pierre Sommadossi, Ph.D., Richard Axel, M.D., Chi Van Dang, M.D., Ph.D., and Richard Scheller, Ph.D.
    2. Cornerstone Pharmaceuticals, Inc. Presents Phase I Data on CPI-613 in Acute Myeloid Leukemia (AML) and T-Cell Non-Hodgkins Lymphoma (T-cell NHL) at ASH 2016
    3. Cornerstone Pharmaceuticals Appoints Brian Mullaney, M.D., Ph.D., as Chief Medical Officer
    4. Cornerstone Pharmaceuticals to Present New Data on CPI-613 at the American Society of Hematology 2016 Annual Meeting
    5. Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon
    6. HelpMeSee & Cornerstone Assistance Showcase MSICS In Texas
    7. Cornerstone Therapeutics Inc. Stockholders Seeking More Money Regarding the Proposed Buyout by Chiesi Farmaceutici S.P.A. Encouraged to Contact Lawyers at Deans & Lyons
    8. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
    9. Purcell Julie & Lefkowitz LLP Is Investigating HedgePath Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
    10. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Anthera Pharmaceuticals, Inc. (ANTH)
    11. Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    Post Your Comments:
    (Date:2/20/2020)... Calif. (PRWEB) , ... February 20, 2020 , ... ... focused on addressing unmet needs in the field of urology, today announced that ... UroLift® Center of Excellence. The designation recognizes that Dr. Uberoi has achieved a ...
    (Date:2/19/2020)... ... ... A new study released today in STEM CELLS Translational Medicine is the ... compressed spinal cord. It is also the first to show how transplanting basic growth ... the injured spinal cord’s recovery. , The study, conducted on a rat model ...
    (Date:2/19/2020)... ... ... Drs. Mario Canal and Ben Calem will host the Pinnacle Dental Study Club ... course features guest speaker, Dr. Amanda Seay, and will focus on aesthetic dentistry as ... full mouth dental implants, are a major focus at Canal Calem Periodontics as a ...
    Breaking Medicine Technology:
    (Date:2/19/2020)... (PRWEB) , ... February 19, 2020 , ... ... the film industry. While he is most known for his acting abilities demonstrated ... host on the educational show “Behind The Scenes” with Laurence Fishburne. “Behind The ...
    (Date:2/19/2020)... ... February 19, 2020 , ... In 2017, the ... regulations and requirements that currently govern medical device manufacturers under the Medical Devices ... 25 May 2020. Major changes from the previous MDD include:, ...
    (Date:2/19/2020)... ... February 19, 2020 , ... ... will highlight its growing product portfolio for lower extremities at the American College ... B. Gonzalez Convention Center. The Trigon® Ti Stand-Alone Osteotomy Wedge Fixation System will ...
    (Date:2/19/2020)... ... February 19, 2020 , ... SafiraMD Medical Aesthetics & ... CoolSculpting®, the world’s most popular non-invasive fat reduction treatment. Their CoolEvent will be ... Village Center in Alpharetta, Georgia. The CoolEvent will feature live demonstrations, exclusive discounts, ...
    (Date:2/16/2020)... ... February 16, 2020 , ... Canadian digital healthcare portal Ask The ... who are concerned about the Coronavirus. , "It is our duty and it is ... this deadly virus" said Prakash Chand, CEO of Ask The Doctor. , Doctors and ...
    Breaking Medicine News(10 mins):